On December 17, 2025, C-MER MEDICAL (03309) announced that it had entered into a deed with Mingda Eyewear. Under the agreement, the company agreed to transfer the sale shares back to Mingda Eyewear, representing 55% of Apollo's total issued share capital.

The transaction consideration involves Mingda Eyewear canceling and returning RMB 50.49 million in bonds previously issued by the company, thereby releasing C-MER MEDICAL from all obligations under the bonds. Upon completion, Apollo will cease to be a non-wholly owned subsidiary of the company, and C-MER MEDICAL will no longer hold any equity interest in Apollo.

The company stated that the group has implemented several strategic initiatives, including focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen. The sale aligns with the group's strategy to optimize internal resource allocation.